CYP3A4 and acute kidney injury: The influence of polymorphisms in CYP3A4 on clinical outcomes was evaluated in four studies: AKI in four studies (Hamadeh et al., 2019; Ho et al., 2024; Khaled et al., 2016; Zhu et al., 2020), GVHD in three studies (Ho et al., 2024; Khaled et al., 2016; Suetsugu et al., 2019), TMA in one study (Khaled et al., 2016) and OS, RFS and NRM in one study (Ho et al., 2024).